RESUMEN

This review focuses on possibilities of using soluble ST2 as a HF marker for diagnostics, stratification of risk of adverse events, and for evaluation of prognosis and treatment effectiveness in patients with CHF. Circulating biomarkers are an essential element of algorithms for diagnostics, stratification of risk, and evaluation of prognosis in patients with HF. The recognized "gold standard", natriuretic peptides, has several well-known limitations, and multiple new candidate biomarkers have appeared in recent years. Soluble ST2, a marker of "mechanical myocardial stress", is considered as one of the most promising new biomarkers. This review discusses possibilities of using it in clinical practice in CHF patients.

Asunto(s)

Biomarcadores , Insuficiencia Cardíaca , Proteína 1 Similar al Receptor de Interleucina-1 , Receptores de Superficie Celular , Biomarcadores/análisis , Insuficiencia Cardíaca/diagnóstico , Humanos , Proteína 1 Similar al Receptor de Interleucina-1/análisis , Péptido Natriurético Encefálico , Pronóstico , Medición de Riesgo